We could not find any results for:
Make sure your spelling is correct or try broadening your search.
NEW YORK, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Deutsche Bank today announced the lineup for its Depositary Receipts Virtual Investor Conference (“dbVIC”) on Wednesday, November 8 and Thursday...
New Data from the Open-Label PLEO-CMT-FU Trial Shows Sustained Benefit with PXT3003 in Patients with Charcot-Marie-Tooth Disease Type 1A After 5 Years of Total Trial Time New Data from the...
Interim Analysis from the Ongoing Open-Label Phase III Extension Study Shows Sustained Benefits of PXT3003 for Patients with Charcot-Marie-Tooth Disease Type 1A (‘CMT1A’) New results suggest good...
Une analyse intermédiaire de l’étude de Phase III d’extension en ouvert en cours montre un benefice durable du traitement avec PXT3003 chez les patients atteints de la maladie de...
Diese Zustimmung bereitet den Weg für die Stellung eines Marktzulassungsantrags in Europa Pharnext SA (Paris:ALPHA) (FR0011191287 – ALPHA), ein biopharmazeutisches Unternehmen und...
This agreement paves the way for the submission of a marketing authorization application in Europe Regulatory News: Pharnext SA (Paris:ALPHA) (FR0011191287 – ALPHA), a...
Pharnext SA (Paris:ALPHA) (FR0011191287 - ALPHA), ein biopharmazeutisches Unternehmen und Vorreiter eines neuen Ansatzes zur Entwicklung innovativer Medikamentenkombinationen, die auf Big...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0.0002 | 0.0002 | 0.0002 | 0 | 0 | DE |
4 | 0 | 0 | 0.0002 | 0.0002 | 0.0002 | 0 | 0 | DE |
12 | 0 | 0 | 0.0002 | 0.0002 | 0.0002 | 0 | 0 | DE |
26 | -0.0318 | -99.375 | 0.032 | 0.042 | 0.0001 | 3089983 | 0.0012115 | DE |
52 | -0.0044 | -95.652173913 | 0.0046 | 1.21 | 0.0001 | 26222057 | 0.00084405 | DE |
156 | -0.0898 | -99.7777777778 | 0.09 | 1.95 | 0.0001 | 61388886 | 0.00380228 | DE |
260 | -4.2398 | -99.9952830189 | 4.24 | 7 | 0.0001 | 37554276 | 0.00730074 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions